Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Irbedrosaph - Philippines FDA Drug Approval Details

Approvals/Philippines FDA/Irbedrosaph

Approved

STANDARD

Irbedrosaph

Sapphire Lifesciences Pvt. Ltd.🇵🇭 Food and Drug Administration - Philippines

Approval Date: Jul 14, 2025
Approval ID: 9c5da0eacd012e36
Company: Sapphire Lifesciences Pvt. Ltd.
Type: Standard

Approval Details

Approval Id: 9c5da0eacd012e36
Drug Approval Philippines Name: Irbedrosaph
Product Name: Irbedrosaph
Registration Number: DRP-12895
Brand Name: Irbedrosaph
Generic Name: Irbesaph + Hydrochlorothiazide
Dosage Form: Film-Coated Tablet
Dosage Strength: 300mg/12.5 mg
Manufacturer: Sapphire Lifesciences Pvt. Ltd.
Importer: Ollen Pharma Trading, Inc.
Distributor: Ollen Pharma Trading, Inc.
Issuance Date: 26 October 2022
Expiry Date: 26 October 2027
Classification: Prescription Drug (RX)

Active Ingredients

Approved

Quick Info

Agency

Philippines FDA

Country

🇵🇭

Approval Date

Jul 14, 2025

Approval ID

9c5da0eacd012e36

Type

Standard

Back to Philippines FDA Approvals